Holen Sie sich die Stockscreener-App
8.77
0.23%
-0.02
Handel nachbörslich:
8.79
0.02
+0.23%
Schlusskurs vom Vortag:
$8.79
Offen:
$8.77
24-Stunden-Volumen:
1.49M
Relative Volume:
0.47
Marktkapitalisierung:
$1.48B
Einnahmen:
$68.56M
Nettoeinkommen (Verlust:
$-437.99M
KGV:
-2.7719
EPS:
-3.1639
Netto-Cashflow:
$-396.61M
1W Leistung:
-5.60%
1M Leistung:
-18.42%
6M Leistung:
+59.45%
1J Leistung:
+90.65%
1-Tages-Spanne:
$8.545
$8.87
1-Wochen-Bereich:
$8.545
$9.57
52-Wochen-Spanne:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.77 | 1.48B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
VIR: Vir Biotechnology Prepares to Present Trial Data at EASL Co - GuruFocus
Vir Biotechnology to present hepatitis delta trial data at EASL - Investing.com
Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com - Investing.com Australia
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TipRanks
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - The Motley Fool
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares - sharewise.com
Boxer Capital Management Boosts Vir Biotechnology Holdings in Q1 2026 FilingNews and Statistics - IndexBox
User | bigspringherald.comVir Biotechnology, Inc.Common Stock (Nasdaq:VIR) Stock Quote - FinancialContent
Vir Biotechnology rated buy on strong cash, late-stage drugs, and key partnerships through 2028 - Pluang
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR) - Seeking Alpha
SoftBank group reports 10.95M-share stake in Vir Biotechnology (VIR) - Stock Titan
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc.Common Stock (NQ: VIR - FinancialContent
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Vir Biotech May 2026 slides: CHD combo hits 88% viral suppression - Investing.com Australia
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips - Investing.com
Q2 EPS Estimates for Vir Biotechnology Cut by HC Wainwright - MarketBeat
TradingKey - TradingKey
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next - simplywall.st
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - Yahoo Finance
A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Vir (VIR) Q1 2026 Earnings Call Transcript - AOL.com
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Vir Biotechnology (VIR) Eps Diluted (TTM) - Zacks Investment Research
Vir Biotechnology Signals Momentum in Latest Earnings Call - TipRanks
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30 - Moomoo
Vir Biotechnology Q1 2026 earnings preview - MSN
Evercore Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028 - MSN
Moderna, Vir among early 2026 top infectious disease gainers - BioWorld News
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
Vir Biotechnology 1Q 2026: Revenue ($29K), Net income ($125.7M), EPS ($0.85) — 10-Q Summary - TradingView
Vir Biotechnology Q1 Earnings Call Highlights - MarketBeat
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results - BioSpace
Vir Biotechnology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com India
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Astellas collaboration brings $315M to Vir Biotechnology (VIR) - Stock Titan
Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results - MarketBeat
Vir Biotechnology schedules Q1 2026 earnings call for 4:30 p.m. ET - Traders Union
Vir Biotechnology Q1 net loss widens - TradingView
Vir Biotechnology (Nasdaq: VIR) extends cash runway into 2H 2028 - Stock Titan
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):